Article
Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) - 1 Nov 2011
Han Ji-Youn, Kim Jin Young, Lee Suk Hyung, Yoo Nam Jin, Choi Byung Gil
Abstract excerpt
PURPOSE: It has been suggested that hepatocyte growth factor (HGF) and insulin-like growth factor binding protein (IGFBP)-3 are associated with gefitinib resistance in non-small cell lung cancer (NSCLC). We investigated the predictive and prognostic roles of these proteins in NSCLC patients treated with gefitinib. PATIENTS AND METHODS: Of 106 patients enrolled in a randomized phase II study of gefitinib, 97 had...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
